Calamos Advisors LLC Purchases Shares of 8,152 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Calamos Advisors LLC purchased a new stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 8,152 shares of the biopharmaceutical company’s stock, valued at approximately $584,000.

Several other hedge funds have also modified their holdings of the company. Xponance Inc. lifted its position in shares of Intra-Cellular Therapies by 3.0% during the fourth quarter. Xponance Inc. now owns 5,676 shares of the biopharmaceutical company’s stock valued at $407,000 after buying an additional 163 shares during the last quarter. Regal Investment Advisors LLC increased its holdings in shares of Intra-Cellular Therapies by 1.4% during the third quarter. Regal Investment Advisors LLC now owns 13,610 shares of the biopharmaceutical company’s stock valued at $709,000 after acquiring an additional 186 shares in the last quarter. State Board of Administration of Florida Retirement System increased its holdings in shares of Intra-Cellular Therapies by 0.8% during the third quarter. State Board of Administration of Florida Retirement System now owns 26,796 shares of the biopharmaceutical company’s stock valued at $1,396,000 after acquiring an additional 200 shares in the last quarter. Global Retirement Partners LLC increased its holdings in shares of Intra-Cellular Therapies by 13.8% during the third quarter. Global Retirement Partners LLC now owns 1,753 shares of the biopharmaceutical company’s stock valued at $89,000 after acquiring an additional 213 shares in the last quarter. Finally, Los Angeles Capital Management LLC increased its holdings in shares of Intra-Cellular Therapies by 2.5% during the third quarter. Los Angeles Capital Management LLC now owns 15,364 shares of the biopharmaceutical company’s stock valued at $800,000 after acquiring an additional 371 shares in the last quarter. 92.33% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Intra-Cellular Therapies

In other news, EVP Suresh K. Durgam sold 6,450 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $66.56, for a total transaction of $429,312.00. Following the sale, the executive vice president now owns 16,170 shares of the company’s stock, valued at approximately $1,076,275.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Michael Halstead sold 7,345 shares of the stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $65.97, for a total transaction of $484,549.65. Following the transaction, the executive vice president now owns 19,803 shares in the company, valued at approximately $1,306,403.91. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Suresh K. Durgam sold 6,450 shares of the stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $66.56, for a total value of $429,312.00. Following the transaction, the executive vice president now owns 16,170 shares in the company, valued at approximately $1,076,275.20. The disclosure for this sale can be found here. Insiders have sold 168,487 shares of company stock valued at $11,364,950 in the last 90 days. 3.40% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

ITCI has been the topic of several recent analyst reports. TD Cowen upped their price objective on shares of Intra-Cellular Therapies from $80.00 to $90.00 and gave the company a “buy” rating in a report on Wednesday, April 17th. Royal Bank of Canada restated an “outperform” rating and set a $86.00 price objective on shares of Intra-Cellular Therapies in a report on Wednesday, April 3rd. The Goldman Sachs Group upped their price objective on shares of Intra-Cellular Therapies from $67.00 to $77.00 and gave the company a “neutral” rating in a report on Wednesday, April 17th. Robert W. Baird upped their price objective on shares of Intra-Cellular Therapies from $83.00 to $103.00 and gave the company an “outperform” rating in a report on Wednesday, April 17th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $101.00 price objective on shares of Intra-Cellular Therapies in a report on Friday, February 23rd. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $88.00.

Intra-Cellular Therapies Trading Up 3.0 %

Shares of NASDAQ:ITCI opened at $74.54 on Tuesday. Intra-Cellular Therapies, Inc. has a twelve month low of $45.50 and a twelve month high of $84.89. The company’s 50 day moving average is $69.34 and its 200 day moving average is $64.36. The company has a market cap of $7.22 billion, a PE ratio of -51.05 and a beta of 1.02.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.14. The business had revenue of $132.10 million for the quarter, compared to analysts’ expectations of $135.97 million. Intra-Cellular Therapies had a negative net margin of 30.08% and a negative return on equity of 23.02%. The business’s revenue was up 50.3% on a year-over-year basis. During the same quarter last year, the company earned ($0.45) EPS. Equities research analysts predict that Intra-Cellular Therapies, Inc. will post -0.67 earnings per share for the current fiscal year.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.